ADCC-Inducing Antibody Trastuzumab and Selection of KIR-HLA Ligand Mismatched Donors Enhance the NK Cell Anti-Breast Cancer Response

Keyphrases

• Trastuzumab 100%
• Anticancer Immune Response 100%
• Natural Killer Cells 100%
• Mismatched Related Donor 100%
• Anti-breast Cancer 100%
• KIR HLA Ligands 100%
• Breast Cancer 15%
• Tumor Microenvironment 15%
• Patient-derived 15%
• Breast Cancer Cells 15%
• Tumor 10%
• Hypoxia 10%
• Tumor Cells 10%
• Cell Response 10%
• KIR Ligand 10%
• SKBR3 10%
• Suppressive Factor 10%
• Treatment Options 5%
• Clinically Significant 5%
• Combination Therapy 5%
• Cytotoxicity 5%
• Immune Response 5%
• Antitumor Immune Response 5%
• Normoxic Conditions 5%
• Hypoxic Condition 5%
• Patient Tumor 5%
• Antitumor Efficacy 5%
• Natural Killer 5%
• Cell-based 5%
• Interleukin-2 5%
• Cell-mediated 5%
• Strategies to Overcome 5%
• HER2 Overexpression 5%
• Antibody-dependent Cellular Cytotoxicity 5%
• CD107a 5%
• Tumor Targeting 5%
• Natural Killer Cell Activity 5%
• MCF-7 5%
• Alloreactive 5%
• Donor-derived 5%
• 4T1 Breast Cancer 5%
• Cell Inhibition 5%
• Cell Functionality 5%
• Natural Killer Cell Degranulation 5%
• SKBR3 Cells 5%
• Targeting Antibodies 5%
• Cancer Cell Cytotoxicity 5%
• Antitumor Potential 5%
• Natural Killer Cell Receptors 5%
• Inhibitory Ligands 5%
• Anti-HER2 Antibody 5%
• Cell Suppression 5%
• HLA Class I Expression 5%
• Cell Donors 5%
• Tumor Environment 5%
• Cultured Cell Lines 5%

INIS

• antibodies 100%
• cancer 100%
• breasts 100%
• ligands 100%
• natural killer cells 100%
• tumors 43%
• patients 17%
• toxicity 13%
• suppression 8%
• hypoxia 8%
• mice 8%
• tumor cells 8%
• therapy 4%
• receptors 4%
• comparative evaluations 4%
• inhibition 4%
• cytokines 4%
• mimic 4%
• environment 4%
• immunotherapy 4%

Immunology and Microbiology

• Trastuzumab 100%
• Natural Killer Cell 100%
• Antibody-Dependent Cell-Mediated Cytotoxicity 100%
• Cancer Cell 14%
• Immune Response 9%
• Cytotoxicity 9%
• Tumor Cell 9%
• Natural Killer Cell Response 9%
• Cytokine 4%
• Cell Line 4%
• Cell Culture 4%
• Interleukin 2 4%
• Degranulation 4%
• Cell Activation 4%
• Immunotherapy 4%